Merck's $2B Bet on Weight-Loss Pill!

Merck just signed a $2 billion deal with China’s Hansoh Pharma for an experimental weight-loss pill targeting the booming obesity drug market, projected to hit $100 billion annually by the 2030s. This GLP-1-based drug aims to compete with blockbuster injections like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro. Merck’s move could expand beyond weight loss to tackle diabetes, cardiovascular issues, and fatty liver disease. The race for innovative obesity treatments is heating up! #Merck, #WeightLossPill, #ObesityDrugs, #GLP1, #PharmaNews, #NovoNordisk, #EliLilly, #HealthInnovation, #WealthyBusiness, #MedicalBreakthroughs